Trump's drug-pricing push could benefit China's biotech sector

POLITICO reports that Trump's drug-pricing push is pressuring European governments to pay more for medicines. Drugmakers warn they will stop launching new medicines there unless governments pay more, and industry figures worry that could accelerate a shift toward more affordable Chinese drug discoveries. ING Healthcare says one in three new drugs in global development pipelines originates from China, up from 4% in 2015. A Trump administration official acknowledged the risk but said Washington would continue its approach.